Textbook of Personalized Medicine - Second Edition [2015]

252

Table 10.4 Clinical trials of personalized cancer vaccines

Vaccine Sponsor Description/indication Phase/status
AGS-003
autologous
DC vaccine

Argos Therapeutics Arcelis™ Personalized

Immunotherapy: DCs pulsed with

amplifi ed mRNA from the

patient’s tumor/metastatic renal

cell carcinoma

Phase II

BiovaxID ® Biovest
International
Inc

Patient-specifi c active

immunotherapy/mantle cell

lymphoma and follicular

non- Hodgkin’s lymphoma

Phase II/III

Compassionate

use in Europe

CVac™:
dendritic cell
(DC)/
auto-logous
vaccine

PrimaBiomed DCs + mannan fusion protein

(adjuvant mannan, attached to a

tumor cell surface protein, mucin

1)/ovarian cancer

Phase IIb

DC/autologous
vaccines

Northwest

Biotherapeutics

1. DCVax ® -Prostate/cancer of
   prostate
   
   
   1. Phase III/US
   
   
   
   


2. DCVax ® -Brain/glioblastoma
   multiforme
   2. Phase II/US

FANG™
Vaccine

Gradalis Inc Autologous tumor cell vaccine

expresses rhGM-CSF and the

bifunctional RNAi effector,

bi-shRNAfurin/

Phase II

HER2/neu
hybrid
vaccine

Antigen Express Peptide immunotherapeutic/HER2/

neu positive breast cancer

Phase II

Imetelstat
(GRNVAC1)

Geron Corporation Autologous DCs loaded ex vivo with

telomerase reverse transcriptase/

metastatic prostate cancer

Phase II

MGN1601 Mologen Gene-modifi ed tumor cells based on
MIDGE (Minimalistic
Immunogenically Defi ned Gene
Expression) vectors/kidney cancer

Phase I

MyVax ® Genitope
Corporation

Designed to activate a patient’s

immune system to identify and

attack cancer cells/follicular

non-Hodgkin’s lymphoma

Phase III

Oncophage
(now called
Prophage,
except in
Russia)

Agenus Inc Renal cancer and malignant

melanoma

Phase III in US

Marketed in

Russia

OncoVAX Vaccinogen Inc Vaccine from the patient’s own tumor
cells, which are irradiated to make
them non-carcinogenic/colorectal
cancer

Phase III

(continued)

10 Personalized Therapy of Cancer